Extended-release matrix tablet of a weakly basic BCS Class II drug: why exposure halves in the fasted gut
Your company is developing a 100 mg extended-release matrix tablet of compound X, a weak base (pKa 8.4, logP 3.1) with high Caco-2 permeability (18 x 10^-6 cm/s) and aqueous solubility of 6.0 mg/mL at pH 1.2 but only 0.03 mg/mL at pH 6.8. The formulation contains 30% w/w HPMC K100M with microcrystalline cellulose and lactose; no pH-modifying excipient is included. In USP Apparatus II at 75 rpm, 12% is released in 0.1 N HCl over 2 h, and after transfer to pH 6.8 phosphate buffer 78% is released by 12 h. In a fasted two-way crossover in 12 volunteers against the immediate-release reference (Cmax 320 ng/mL, AUC0-inf 1450 ng.h/mL, tmax 1.5 h), the ER tablet gave Cmax 95 ng/mL, AUC0-inf 760 ng.h/mL and tmax 5 h. A fed-state arm of the same study gave AUC0-inf 1180 ng.h/mL. Faecal recovery of unchanged drug over 72 h was 38% of the administered dose.
1. Account mechanistically for the approximately 52% relative bioavailability in the fasted state and for the improvement seen after a meal.
Read the worked answer
Start from the dose/solubility ratio. A 100 mg dose in a realistic 250 mL of intestinal fluid requires 0.4 mg/mL to dissolve completely, but at pH 6.8 the solubility is 0.03 mg/mL, so roughly 3.3 L of fluid would be needed. The drug is therefore dissolution-rate limited in the small intestine even though permeability is high, i.e. a true BCS Class II profile that the formulation has made worse.
HPMC erosion releases drug slowly along the whole gut, but the fraction released distal to the absorption window meets a medium of low solubility and short residence time. Once the matrix hydrates, the microenvironment pH inside the gel is set by the polymer and the drug itself, not by the bulk lumen, so the free base precipitates as the soluble fraction is absorbed (a classic 'spring-and-parachute' failure without a parachute). This explains the 38% faecal recovery of parent drug and the flat, low Cmax.
Food raises gastric pH buffering and residence time, increases bile salt and lipid solubilisation, and slows transit, giving more time for dissolution in the proximal gut; hence AUC rises from 760 to 1180 ng.h/mL. The 2 h acid stage of the dissolution test over-rewards the formulation by dissolving drug that in vivo would never have met pH 1.2 for that long in the presence of a food bolus.
2. Propose two formulation strategies to recover exposure, with the physicochemical rationale, and state the in vitro evidence that would support each.
Read the worked answer
Strategy 1: create an acidic microenvironment. Add 10-20% w/w fumaric or tartaric acid (or an acidic salt of the drug, e.g. the hydrochloride, if it is stable) inside the matrix so that the dissolving fluid around the particle stays below pH 5, where solubility is >1 mg/mL. Evidence: a two-stage dissolution test (0.1 N HCl 2 h, then pH 6.8 buffer without surfactant) showing at least 80% release in 12 h with the same profile across pH 4.5, 6.8 and 7.4 media, plus absence of gelling/precipitation on the paddle.
Strategy 2: present the drug amorphously as a solid dispersion. Spray-dry the base with HPMC-AS or PVP-VA at 1:3 w/w so that the polymer maintains supersaturation after release, then compress the dispersion into an ER matrix. Evidence: dissolution with a supersaturation ratio of at least 10 maintained for 4 h without crystalline conversion (confirmed by XRPD and DSC on the recovered solid), and a non-sink test rather than a sink test, because sink conditions hide exactly the failure you are trying to detect.
A third, pragmatic option is to lower the strength or move to a biphasic (IR overlay plus ER core) design if the pharmacokinetic target allows it.
3. Can a Level A in vitro-in vivo correlation be established for this product and would a biowaiver be available?
Read the worked answer
A Level A IVIVC is theoretically attainable but would require more than the data you have. You need at least three formulations with genuinely different release rates (for example 6 h, 12 h and 18 h profiles), each dosed in a crossover in fasted humans, followed by deconvolution of plasma data (Wagner-Nelson for a one-compartment drug, Loo-Riegelman if distribution is biexponential) to obtain fraction absorbed versus time. Fraction absorbed is then plotted against fraction dissolved from a biorelevant test. Given the pH-dependent solubility, the in vitro side must be a two-stage or transfer system using FaSSIF/FeSSIF or a bicarbonate-buffered pH 6.5 medium, not a simple sink dissolution, otherwise the correlation will be coincidental across the three formulations and will fail the internal predictability check (+/-10% for Cmax and AUC).
A biowaiver is not available: BCS-based biowaivers apply to immediate-release solid oral products of Class I and III drugs (and Class II only under specific, restricted conditions in some jurisdictions), and this is a modified-release product with a documented bioavailability problem. The ER tablet will need full in vivo bioequivalence, plus a food-effect study, and the regulatory dossier should justify the dissolution method by discriminating power against deliberately altered batches.